AIM ImmunoTech Inc.
AIM
Rank in Stocks
#29998
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida,... AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Share Price
$0.157
Last synced: 2026-11-09
Market Cap
$6.26M
Change (1 day)
1.29%
Change (1 year)
-89.39%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade AIM ImmunoTech Inc. (AIM)
Category
Healthcare
EPS for AIM ImmunoTech Inc. (AIM)
EPS as of June 2026 TTM: $-3.84
According to AIM ImmunoTech Inc.'s latest financial reports, its current EPS (TTM) is $-3.84. At the end of 2025 the company had an EPS of $-8.62, an increase over its 2024 EPS of $-11.22.
EPS history for AIM ImmunoTech Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-3.84 | -55.45% |
| 2025 | $-8.62 | -23.20% |
| 2024 | $-11.22 | -48.13% |
| 2023 | $-21.64 | 47.29% |
| 2022 | $-14.69 | 0.17% |
| 2021 | $-14.67 | -10.66% |
| 2020 | $-16.41 | -82.48% |
| 2019 | $-93.71 | -73.62% |
| 2018 | $-355.19 | -23.32% |
| 2017 | $-463.19 | -14.71% |
| 2016 | $-543.05 | -52.78% |
| 2015 | $-1.15K | -33.33% |
| 2014 | $-1.72K | -10.00% |
| 2013 | $-1.92K | -16.67% |
| 2012 | $-2.30K | 71.43% |
| 2011 | $-1.34K | -30.00% |
| 2010 | $-1.92K | 42.86% |
| 2009 | $-1.34K | -56.25% |
| 2008 | $-3.07K | -36.00% |
| 2007 | $-4.79K | -19.35% |
| 2006 | $-5.94K | 29.17% |
| 2005 | $-4.60K | 4,391.55% |
| 2004 | $-102.41 | 24.26% |
| 2003 | $-82.42 | 85.84% |
| 2002 | $-44.35 | -19.93% |
| 2001 | $-55.39 | -1.16% |
| 2000 | $-56.04 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -507.81% |
US
|
|
| $-7.07 | 84.11% |
US
|
|
| $-5.29 | 37.76% |
AU
|
|
| $12.88 | -435.42% |
BE
|
|
| $21.56 | -661.46% |
NL
|
Questions about AIM ImmunoTech Inc.'s earnings per share (EPS)
What is AIM ImmunoTech Inc.'s earnings per share (EPS)?
AIM ImmunoTech Inc.'s earnings per share (EPS) over the last twelve months is $-3.84, as of Jun 2026.
What was AIM ImmunoTech Inc.'s earnings per share (EPS) in 2025?
In 2025, AIM ImmunoTech Inc.'s earnings per share (EPS) was $-8.62, compared with $-11.22 in 2024.
How has AIM ImmunoTech Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, AIM ImmunoTech Inc.'s earnings per share (EPS) was highest in 2025 ($-8.62) and lowest in 2023 ($-21.64).
How does AIM ImmunoTech Inc.'s earnings per share (EPS) compare with similar companies?
AIM ImmunoTech Inc.'s earnings per share (EPS) ($-3.84) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.